Zurcher Kantonalbank (Zurich Cantonalbank) Fate Therapeutics Inc Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$34.1 Billion
Q4 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	BUY	$9.86 - $23.83 $46,194 - $111,643	4,685 Added 46.97%	14,660 $147,000
Q1 2022 Apr 21, 2022	SELL	$29.67 - $60.28 $100,432 - $204,047	-3,385 Reduced 25.34%	9,975 $387,000
Q4 2021 Feb 01, 2022	BUY	$47.84 - $64.34 $245,658 - $330,385	5,135 Added 62.43%	13,360 $782,000
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $770 - $1,244	-13 Reduced 0.16%	8,225 $487,000
Q2 2021 Jul 30, 2021	BUY	$67.25 - $92.52 $2,152 - $2,960	32 Added 0.39%	8,238 $715,000
Q1 2021 May 03, 2021	SELL	$72.16 - $117.4 $93,158 - $151,563	-1,291 Reduced 13.59%	8,206 $677,000
Q4 2020 Jan 28, 2021	BUY	$38.09 - $100.95 $98,005 - $259,744	2,573 Added 37.16%	9,497 $864,000
Q2 2020 Jul 28, 2020	BUY	$20.21 - $35.23 $35,266 - $61,476	1,745 Added 33.69%	6,924 $238,000
Q1 2020 May 06, 2020	BUY	$17.28 - $31.88 $38,793 - $71,570	2,245 Added 76.52%	5,179 $115,000
Q1 2019 Apr 29, 2019	SELL	$13.15 - $18.71 $12,242 - $17,419	-931 Reduced 24.09%	2,934 $52,000
Q4 2018 Jan 25, 2019	BUY	$11.48 - $16.98 $16,806 - $24,858	1,464 Added 60.97%	3,865 $50,000
Q3 2018 Nov 09, 2018	BUY	$8.75 - $16.29 $21,008 - $39,112	2,401 New	2,401 $39,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

108M

Call Options Held

79.2K

Put Options Held

Redmile Group, LLC San Francisco, CA

12.9M
Shares

$18.3 Million
1.66% of portfolio
Vanguard Group Inc Valley Forge, PA

10.3M
Shares

$14.7 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$14.4 Million
0.0% of portfolio
Bellevue Group Ag Kuesnacht, V8

4.84M
Shares

$6.87 Million
0.16% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

4.38M
Shares

$6.22 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account